Spain and Portugal operate robust neuropathy cell therapy programmes with published registries and long-term follow-up. South Korea offers high-volume, rapid access with competitive pricing and established diabetic neuropathy protocols. Mexico provides cost-effective treatment with reasonable regulatory oversight. Germany maintains rigorous protocols but at higher cost. For comprehensive outcome tracking and evidence integration, Spanish and Portuguese centres are preferred; for rapid, affordable access, South Korea and Mexico offer pragmatic alternatives.
Neuropathy cell therapy costs €4,000–6,500 depending on delivery method and cell source. Systemic intravenous MSC infusion (€4,500–5,500) is most accessible. Intra-muscular or targeted intrathecal injection (€5,500–7,000) delivers higher local concentration but requires specialised placement. Exosome therapy (€4,000–5,500) is emerging with competitive pricing. Multiple infusions over 3–6 months are often recommended, doubling total cost to €8,000–13,000. Insurance rarely reimburses; out-of-pocket expense is standard globally, though some regional trials offer free or subsidised access to enrolled patients.
Am I a candidate? → · Peripheral Neuropathy: full overview → · Peripheral Neuropathy cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment